Julia Belluz
speaker
540 appearances
2 recordings
2 series
first heard Feb 2026
last heard 8 May
Julia Belluz’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in May 2026 with 1.
Appearances
They seem to lower inflammation.
And this, to me, is the most exciting area because we've had drugs in the past that kind of shut down inflammation, like steroids, let's say.
But you put people at risk because you're essentially shutting down the immune system.
You're putting people at higher risk for cancer or other infections.
But the way this is described to me is that GLP-1 seem to act as these fine tuners of inflammation.
So they have this more subtle approach and it's not something we've really had in medicine before.
So we're using these drugs.
So GLP-1 and there's other drugs that are coming on the market with like the dual and triple agonists that use more than GLP-1.
And the question is, like, are we going to discover these other hormones that we can subtly manipulate the immune system and inflammation with?
And so we might just be at the beginning of this.
And I think the other exciting facet of it is we might really get amazing insights into the immune system through these drugs that we haven't had before because we haven't been able to do these more subtle manipulations.
But the third way these drugs seem to help people is by directly targeting the organs that are involved in particular diseases.
So sending signals to the liver to heal scarring involved in fatty liver disease or to clear the fat from the liver or whatever it is to promote healing in the liver or the kidneys.
So that's a third way these drugs seem to be helping people.
Your guess is as good as mine.
There's models in mice of what's going on, but how this is working inside of us, we don't know.
No, I had the same question as you.
And the deeper I dive into the science, the more I've wondered the same thing.
We did this poll with the Times for a piece of GLP-1 users and asked them, like, what's your experience been like?
And I went into that poll thinking we would get these kind of negative results.
Showing 201–220 of 540 · page 11 of 27
← Previous
Next →